Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

As different stocks rise and fall, so do dividend yields, creating a shifting landscape of opportunities for income-oriented ...

Kenvue (KVUE), the company behind Tylenol and Neutrogena, announced that Thibaut Mongon had left the company, naming Kirk ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

This was the stock's third consecutive day of losses.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.